Us Congress 2023-2024 Regular Session

Us Congress Senate Bill SB3464

Introduced
12/12/23  

Caption

FORWARD Act of 2023 Finding Orphan-disease Remedies With Antifungal Research and Development Act of 2023

Impact

The bill proposes the establishment of the Endemic Fungal Disease Working Group, which will coordinate federal efforts to combat these diseases and research gaps. This group will consist of representatives from various federal agencies and non-federal experts, ensuring both breadth and depth in knowledge and strategy formulation. A specific focus of the bill is to expand the tropical disease product priority review voucher program, which incentivizes the development of products aimed at treating endemic fungal diseases. By supporting antifungal product development, the legislation seeks to improve health outcomes for afflicted populations and prevent the spread of these diseases.

Summary

SB3464, titled the FORWARD Act of 2023, aims to enhance research on endemic fungal diseases, particularly coccidioidomycosis, commonly referred to as Valley Fever. The bill mandates continuing support from the National Institutes of Health for research into fungal diseases affecting public health in the United States. This includes funding for basic, translational, and clinical research, and allows for grants to be awarded to various entities engaged in such research. The act recognizes the need for targeted research on these diseases due to their public health implications and the gaps in current therapeutic offerings.

Contention

Despite its comprehensive approach to enhance public health initiatives against fungal diseases, there may be contention regarding the allocation of significant funds—$20 million annually for research and $500 million for broader antimicrobial resistance programs over five years. Critics may argue about the effectiveness of these funding mechanisms or the prioritization of certain diseases over others. Additionally, the establishment of a federal working group may raise questions on bureaucratic efficiency and inter-agency collaboration, emphasizing the need for streamlined processes to avoid duplication of efforts and ensure effective use of resources.

Companion Bills

US HB6731

Same As FORWARD Act of 2023 Finding Orphan-disease Remedies With Antifungal Research and Development Act of 2023

US SB3220

Related A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.

US HB6227

Related Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

Similar Bills

CA AB922

Reproductive health and research: oocyte procurement.

HI SB2304

Relating To The Research Corporation Of The University Of Hawaii.

HI SB3208

Relating To The Research Corporation Of The University Of Hawaii.

HI SB1511

Relating To The Research Corporation Of The University Of Hawaii.

HI SB1511

Relating To The Research Corporation Of The University Of Hawaii.

HI SB1204

Relating To The University Of Hawaii.

CA SB934

California Childhood Cancer Research Fund Act.

CA AB1103

Controlled substances: research.